J.L. Morison to complete manufacturing expansion by Dec
View(s):Hemas Holdings’ US$1 million expansion of J.L. Morison Son and Jones (Ceylon) (JLM) which it acquired in generic pharmaceutical manufacturing operation will be done by year end, officials said.
JLM CEO Trehan Perera told the Business Times that this exercise seeks to upgrade and overhaul their old machinery. Hemas acquired a 88.8 per cent stake (compositely in Voting & Non-Voting ) in J.L. Morison Sons & Jones in May 2013.
“The government’s plan to initiate ‘Guarantee Buy Back’ agreements in a Public-Private Partnership Scheme will see quality medicines at affordable prices for the public,” he said, adding that this was the reason for their expansion plans. “In turn this will give the local manufacturers in the pharmaceutical industry more depth and recognition,” he said. He said that better machinery with higher capacity is being installed. The JLM Group has a portfolio of well-established consumer brands including Lacto Calamine, Valmelix, Morrison’s Gripe Mixture and Morrison’s Baby products. JLM distributes Good Knight, Kiwi, Wipro, Nivea, Garnier and L’Oreal as well as manufacturing and distributing pharmaceutical products island wide. “These are strong brands and they have a strong distribution. JLM complements Hemas’ pharmaceutical presence,” Mr. Perera said.